Global Vascular Graft Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

Global Vascular Graft Market Segmentation, By Product Type (Haemodialysis Grafts, Coronary Artery Bypass Grafts, Peripheral Vascular Grafts, Coronary Stent, and Others), Material (Synthetic grafts, Biosynthetic Grafts, and Biological Grafts), Application (Coronary Artery Bypass, Aneurysms, Renal Failures, and Others), End User (Hospitals, Ambulatory Surgical Centres, and Specialised Clinics), Distribution Channel (Direct Tenders, and Retailers), - Industry Trends and Forecast to 2032

Vascular Graft Market Size

• The global vascular graft market size was valued at USD 2.3 billion in 2024 and is expected to reach USD 3.58 billion by 2032, at a CAGR of 5.72% during the forecast period
• The market growth is largely fueled by increasing prevalence of cardiovascular diseases, rising geriatric population, and growing demand for minimally invasive surgical procedures
• Furthermore, advancements in biomaterials, rising adoption of synthetic and biologic vascular grafts, and increasing investments in cardiovascular healthcare infrastructure are accelerating the uptake of Vascular Graft solutions, thereby significantly boosting the industry's growth

Vascular Graft Market Analysis

• Vascular grafts, used to replace or repair damaged blood vessels, are increasingly vital components of modern cardiovascular treatments in both hospitals and specialty clinics due to their enhanced durability, biocompatibility, and success rates in minimally invasive and open surgeries
• The escalating demand for vascular grafts is primarily fueled by the rising prevalence of cardiovascular diseases, increasing surgical interventions, and growing adoption of advanced endovascular and surgical technologies
• North America dominated the vascular graft market with the largest revenue share of 41.3% in 2024, characterized by advanced healthcare infrastructure, high adoption of cardiovascular interventions, and a strong presence of key industry players, with the U.S. experiencing substantial growth in Vascular Graft procedures, particularly in hospitals and specialty cardiovascular centers, driven by innovations from both established medical device companies and emerging startups focusing on minimally invasive and endovascular technologies
• Asia-Pacific is expected to be the fastest growing region in the vascular graft market during the forecast period, with a projected CAGR from 2025 to 2032, fueled by increasing urbanization, rising prevalence of cardiovascular diseases, and growing healthcare expenditure in countries such as China and India. Expansion of tertiary care hospitals, government health initiatives, and the adoption of advanced endovascular technologies contribute to the region’s rapid market growth
• The coronary artery bypass segment dominated the largest market revenue share of 40.2% in 2024, driven by the increasing prevalence of coronary artery disease, high volume of cardiac surgeries, and established treatment protocols

Report Scope and Vascular Graft Market Segmentation      

Vascular Graft Market Trends

Enhanced Convenience Through Technological Advancements

• A significant and accelerating trend in the global vascular graft market is the increasing adoption of advanced materials, bioengineering techniques, and precision manufacturing processes. This integration of innovative technologies is significantly enhancing the performance, durability, and clinical outcomes of vascular grafts

  • For instance, in March 2023, Terumo Corporation introduced its new line of heparin-bonded vascular grafts designed to reduce thrombogenicity and improve long-term patency rates in coronary and peripheral artery bypass procedures. Similarly, Gore Medical launched next-generation ePTFE grafts with improved flexibility and suture retention for complex vascular surgeries

• Advances in bioresorbable materials and tissue-engineered vascular grafts are enabling better biocompatibility and reduced risk of complications, supporting more reliable implantation outcomes. Some grafts now incorporate surface modifications to enhance endothelialization and reduce infection risks, providing clinicians with more effective options for high-risk patients. Furthermore, improvements in graft design allow for easier surgical handling and customized sizing, addressing patient-specific anatomical challenges
• The seamless integration of advanced materials, design innovations, and minimally invasive delivery systems facilitates improved surgical precision, shorter procedure times, and better post-operative recovery. Through these technological enhancements, patients experience improved clinical outcomes, while healthcare providers benefit from greater procedural efficiency and predictability
• This trend towards more durable, biocompatible, and clinically optimized vascular grafts is fundamentally reshaping expectations in cardiovascular and peripheral interventions. Consequently, companies such as Medtronic and Terumo are developing next-generation vascular grafts with enhanced structural integrity, surface modifications for improved healing, and features supporting minimally invasive deployment
• The demand for vascular grafts with superior performance characteristics, longer durability, and improved patient outcomes is growing rapidly across cardiovascular, peripheral, and renal applications, as healthcare providers increasingly prioritize clinical efficacy and reduced complication rates

Vascular Graft Market Dynamics

Driver

Rising Incidence of Cardiovascular Diseases and Technological Advancements in Grafts

• The increasing prevalence of cardiovascular diseases, peripheral artery disease, and renal complications worldwide is a significant driver for the heightened demand for advanced vascular grafts

  • For instance, in February 2022, Terumo Corporation announced the launch of its next-generation prosthetic vascular grafts optimized for bypass surgeries, aimed at improving patency rates and reducing post-operative complications. Such initiatives by leading companies are expected to drive the Vascular Graft market growth during the forecast period

• As patients and clinicians seek improved outcomes for complex vascular interventions, advanced grafts provide enhanced features such as bioengineered surfaces, higher durability, and reduced thrombogenicity, offering a compelling advantage over traditional grafts
• Furthermore, the growing adoption of minimally invasive procedures and image-guided vascular interventions is increasing the demand for precision-engineered grafts compatible with modern surgical techniques
• The availability of grafts for specialized applications, including coronary, peripheral, and hemodialysis access, combined with improvements in material science, supports broader utilization in diverse clinical settings
• Continuous investment in R&D, coupled with the development of next-generation grafts with enhanced performance and reduced complication rates, further contributes to market growth

Restraint/Challenge

High Costs and Regulatory Challenges

• The relatively high cost of advanced vascular grafts compared to conventional options poses a barrier to adoption, particularly in developing regions or for healthcare facilities with constrained budgets

  • For instance, some next-generation ePTFE and bioengineered grafts are priced significantly higher due to complex manufacturing processes and rigorous clinical testing requirements

• Regulatory approvals for novel graft materials and tissue-engineered products can be time-consuming and stringent, delaying market entry and adoption. Manufacturers must conduct extensive preclinical and clinical evaluations to demonstrate safety, efficacy, and long-term patency, which can increase development timelines and costs
• While technological advancements are improving graft performance, perceived premium pricing can hinder uptake in cost-sensitive healthcare systems
• Overcoming these challenges through strategic partnerships, local manufacturing initiatives, and targeted clinical studies to demonstrate value and cost-effectiveness will be vital for sustained market growth
• Furthermore, increasing awareness among clinicians regarding the long-term benefits of advanced grafts, combined with supportive reimbursement frameworks in key markets, will play a crucial role in accelerating adoption and overall market expansion

Vascular Graft Market Scope

The market is segmented on the basis of product type, material, application, end user, and distribution channel.

• By Product Type

On the basis of product type, the Vascular Graft market is segmented into haemodialysis grafts, coronary artery bypass grafts, peripheral vascular grafts, coronary stents, and others. The coronary artery bypass grafts (CABG) segment dominated the largest market revenue share of 39.8% in 2024, driven by the high prevalence of coronary artery disease, well-established surgical procedures, and widespread adoption in hospitals and specialty clinics. CABG grafts are preferred due to their proven long-term patency, compatibility with patient vasculature, and integration with minimally invasive cardiac surgery programs. Strong healthcare infrastructure in developed regions, combined with favorable reimbursement policies, further reinforces their dominance. Surgeons increasingly rely on advanced CABG grafts with improved biocompatibility and lower thrombogenic risks, supporting sustained market leadership. Advanced imaging and pre-operative planning technologies enhance surgical precision, reduce complications, and improve patient outcomes. Continuous clinical trials and collaborations with research institutes ensure innovations in graft design. The availability of skilled cardiovascular surgeons and cardiac centers also underpins dominance. Market leadership is reinforced by consistent performance, reliability, and hospital preference for standardized procedures. Government initiatives supporting cardiac health, awareness campaigns, and insurance coverage expand access and drive adoption. Hospitals continue to invest in the latest CABG grafts to maintain quality and competitive advantage.

The peripheral vascular grafts segment is anticipated to witness the fastest CAGR of 8.9% from 2025 to 2032, fueled by rising peripheral artery disease prevalence, increasing minimally invasive procedures, and growing awareness among patients and clinicians. Advancements in graft design, such as bioengineered and drug-eluting options, enhance procedural outcomes. Emerging markets are witnessing higher adoption due to expanding hospital networks and improved cardiovascular care infrastructure. Investments in training for endovascular specialists and government-led cardiovascular health programs further accelerate growth. Private clinics and specialty centers are increasingly incorporating peripheral graft solutions to address rising demand. Early diagnosis and rising geriatric populations support market expansion. Technological innovations, such as enhanced flexibility and reduced thrombosis risk, increase adoption. Expansion of reimbursement schemes and insurance coverage further drives uptake. Partnerships between hospitals and manufacturers enhance availability and distribution. Increasing research on long-term outcomes of peripheral grafts stimulates clinical adoption. Awareness campaigns targeting both clinicians and patients contribute to accelerated growth. Rising cardiovascular disease burden in Asia-Pacific and Latin America provides additional growth opportunities. Government initiatives for improved vascular care in emerging regions further strengthen growth.

• By Material

On the basis of material, the Vascular Graft market is segmented into synthetic grafts, biosynthetic grafts, and biological grafts. The synthetic grafts segment dominated the largest market revenue share of 41.5% in 2024, driven by widespread availability, consistent performance, and suitability for various vascular procedures. Synthetic grafts such as PTFE and Dacron offer predictable patency, ease of handling, and long-term durability. Hospitals and surgical centers prefer synthetic options for both coronary and peripheral bypass procedures, supported by established clinical protocols. Increasing investments in product innovation, including surface modifications to reduce infection and thrombosis, further reinforce market leadership. The segment benefits from strong manufacturing capabilities, wide distribution networks, and reliable supply chains. Training programs for surgeons emphasize the use of synthetic grafts for standard procedures. Positive clinical outcomes and long-term studies strengthen confidence in synthetic graft usage. Integration with minimally invasive surgical approaches further supports adoption. Hospitals rely on synthetic grafts for high-volume surgeries due to reproducibility and safety. Partnerships with global medical technology companies enhance research and development. Synthetic grafts’ competitive pricing compared to biosynthetic and biological options drives continued preference. Clinical guidelines recommending synthetic grafts for specific procedures further reinforce dominance. Regulatory approvals for newer synthetic graft designs sustain market leadership.

The biosynthetic grafts segment is expected to witness the fastest CAGR of 9.3% from 2025 to 2032, fueled by technological advancements, increasing clinical trials, and rising adoption in high-risk patient populations. Biosynthetic options combine natural tissue integration with enhanced mechanical strength. They are gaining traction in aneurysm repairs and peripheral reconstructions, particularly in regions with growing R&D infrastructure. Regulatory approvals for newer biosynthetic grafts and rising collaborations between medical device companies and hospitals support rapid growth. Innovation in hybrid grafts and coatings enhances patient outcomes and reduces post-operative complications. Targeted awareness programs for clinicians encourage adoption in complex cases. Early adoption in high-income countries sets a benchmark for emerging markets. Expansion of specialty clinics and tertiary care hospitals increases accessibility. Increasing demand for minimally invasive procedures accelerates uptake. Funding from government and private research initiatives supports new product development. Partnerships between academic institutions and graft manufacturers enhance adoption. Clinical evidence demonstrating superior healing and patency of biosynthetic grafts drives confidence among surgeons. Customization options and patient-specific graft designs further support market growth.

• By Application

On the basis of application, the Vascular Graft market is segmented into coronary artery bypass, aneurysms, renal failures, and others. The coronary artery bypass segment dominated the largest market revenue share of 40.2% in 2024, driven by the increasing prevalence of coronary artery disease, high volume of cardiac surgeries, and established treatment protocols. CABG remains the gold standard for severe stenosis and multi-vessel disease. Hospitals and specialty clinics continue to invest in advanced graft technologies to improve patient outcomes and reduce post-operative complications. Strong reimbursement frameworks, clinical awareness programs, and widespread cardiac care adoption further support segment dominance. Availability of specialized cardiovascular surgeons and high-end surgical facilities enhances adoption. Government health initiatives promoting cardiac care expand access. Long-term clinical studies support the efficacy of CABG grafts. Surgeons rely on advanced imaging and robotic-assisted procedures for precision. Market leadership is strengthened by partnerships with global medical device manufacturers. Hospitals’ procurement policies prioritize proven CABG grafts. Continuous improvements in surgical techniques enhance patient safety. The preference for minimally invasive CABG procedures drives adoption further.

The aneurysms segment is expected to witness the fastest CAGR of 9.1% from 2025 to 2032, fueled by rising incidence of aortic and peripheral aneurysms, increased screening, and adoption of minimally invasive endovascular interventions. Technological advancements, such as custom-sized grafts and stent-graft hybrids, enhance procedural success rates. Growing geriatric populations and awareness initiatives contribute to higher adoption, particularly in Europe and Asia-Pacific regions. Hospitals and specialty centers increasingly adopt advanced aneurysm grafts. Government programs for vascular health encourage early intervention. New product launches with improved biocompatibility and reduced complications drive demand. Training programs for vascular surgeons improve confidence in using these grafts. Insurance coverage for complex procedures boosts uptake. Collaboration between device manufacturers and hospitals accelerates adoption. Awareness campaigns targeting high-risk patients further support growth. Increasing outpatient surgical facilities expand access to aneurysm grafts. Early diagnosis and preventive care initiatives contribute to market expansion.

• By End User

On the basis of end user, the Vascular Graft market is segmented into hospitals, ambulatory surgical centres, and specialized clinics. The hospitals segment dominated the largest market revenue share of 45.7% in 2024, driven by their infrastructure, skilled cardiac and vascular surgeons, and capacity to handle high surgical volumes. Hospitals are preferred due to comprehensive pre- and post-operative care, advanced imaging facilities, and multi-specialty integration. Investments in cutting-edge surgical suites, robotic-assisted vascular surgery, and standardized protocols for graft implantation further reinforce dominance. Access to specialized teams, established procurement systems, and government contracts maintain market leadership. Clinical guidelines support graft selection in hospital settings. Continuous training for medical staff enhances outcomes. Hospitals’ high patient inflow ensures consistent utilization. Partnerships with global medical device companies strengthen supply chains. Hospitals actively participate in clinical trials for new graft technologies. Insurance coverage and reimbursement policies favor hospital-based interventions. Integration with cardiac and vascular programs increases adoption. Hospitals remain central to advanced vascular graft procedures.

The specialized clinics segment is expected to witness the fastest CAGR of 10.4% from 2025 to 2032, fueled by increasing focus on minimally invasive procedures, outpatient interventions, and niche cardiovascular treatments. Expansion of private vascular and cardiac specialty centers, along with rising patient preference for personalized care, drives adoption. Partnerships with medical device manufacturers and adoption of novel graft technologies accelerate growth. Specialty clinics leverage advanced imaging and procedural capabilities for competitive differentiation. Awareness campaigns targeting high-risk patients enhance adoption. Insurance reimbursement for outpatient procedures supports growth. Emerging economies are witnessing rapid expansion of specialty vascular centers. Availability of skilled surgeons and dedicated support staff drives utilization. Private investment in technology upgrades improves operational efficiency. Collaboration with hospitals and research institutes increases access to advanced graft solutions. Continuous innovation in graft design and coatings supports specialty clinic adoption. Government and NGO programs promoting cardiovascular care contribute to growth.

• By Distribution Channel

On the basis of distribution channel, the Vascular Graft market is segmented into direct tenders and retailers. The direct tenders segment dominated the largest market revenue share of 44.3% in 2024, owing to bulk procurement by hospitals and government healthcare institutions. Direct tenders ensure supply chain reliability, competitive pricing, and streamlined regulatory compliance. Strong relationships between manufacturers and healthcare providers, along with long-term contracts, maintain segment dominance. Large-volume orders, institutional partnerships, and pre-negotiated pricing agreements strengthen market control. Hospitals rely on direct tender procurement for consistency. Favorable government regulations facilitate tender-based procurement. Manufacturers benefit from predictable revenue streams. Standardized product specifications simplify bulk orders. Investments in logistics and warehousing optimize delivery. Collaboration with healthcare networks enhances efficiency. Consistent product quality ensures high adoption. Government-led healthcare programs increase demand through tenders.

The retailers segment is expected to witness the fastest CAGR of 11.1% from 2025 to 2032, driven by increasing demand in private clinics, growing awareness about advanced vascular interventions, and rising presence of specialized medical distributors. Retail channels benefit from faster delivery, localized support, and growing adoption in emerging markets, expanding access to vascular grafts beyond major hospital networks. Retailers offer tailored solutions to meet clinic-specific needs. Marketing initiatives and product demonstrations enhance uptake. Private healthcare providers increasingly rely on retail channels for niche graft products. E-commerce adoption in medical supplies improves accessibility. Regional distribution networks strengthen availability. Customer support and training from distributors enhance confidence in usage. Specialized retailers focus on high-demand graft types. Emerging markets benefit from retail penetration. Retail expansion complements direct tender channels.

Vascular Graft Market Regional Analysis

• North America dominated the vascular graft market with the largest revenue share of 41.3% in 2024, characterized by advanced healthcare infrastructure, high adoption of cardiovascular interventions, and a strong presence of key industry players
• The market experienced substantial growth in vascular graft procedures, particularly in hospitals and specialty cardiovascular centers, driven by innovations from both established medical device companies and emerging startups focusing on minimally invasive and endovascular technologies
• High demand for cardiovascular procedures, coupled with increasing awareness of advanced treatment options and strong reimbursement frameworks, has further supported market expansion across the region

U.S. Vascular Graft Market Insight

The U.S. vascular graft market captured the largest revenue share in 2024 within North America, fueled by rapid adoption of advanced cardiovascular interventions, increasing prevalence of peripheral artery and coronary artery diseases, and ongoing initiatives to enhance procedural efficiency and patient outcomes. Growth is further propelled by technological innovations in endovascular devices, bioengineered grafts, and minimally invasive surgical solutions, allowing hospitals and specialty centers to offer advanced treatment options. The presence of a robust healthcare ecosystem, coupled with continuous R&D investment and the emergence of innovative startups, continues to strengthen the U.S. market position.

Europe Vascular Graft Market Insight

The Europe vascular graft market is projected to expand at a substantial CAGR throughout the forecast period, primarily driven by increasing prevalence of cardiovascular diseases, rising demand for minimally invasive procedures, and the presence of well-established healthcare systems. Growth is supported by the adoption of advanced endovascular technologies, government initiatives promoting cardiovascular health, and increasing investment in research and development for innovative graft materials. The region is witnessing significant uptake across hospitals, specialty cardiovascular centers, and diagnostic facilities, with procedures increasingly integrating bioengineered and high-performance grafts.

U.K. Vascular Graft Market Insight

The U.K. vascular graft market is anticipated to grow at a noteworthy CAGR during the forecast period, driven by rising cardiovascular disease incidence, increased awareness of minimally invasive treatment options, and advancements in vascular surgery technologies. The expansion of tertiary care hospitals and specialty centers, along with strong government initiatives to improve cardiovascular outcomes, is expected to support market growth. Additionally, innovations in graft design and the adoption of endovascular procedures contribute to enhanced clinical outcomes and wider acceptance among healthcare providers.

Germany Vascular Graft Market Insight

The Germany vascular graft market is expected to expand at a considerable CAGR during the forecast period, fueled by rising cardiovascular disease prevalence, technologically advanced healthcare infrastructure, and increasing demand for high-performance grafts. Germany’s emphasis on medical innovation and patient-centric care promotes the adoption of bioengineered grafts, minimally invasive techniques, and endovascular technologies, particularly in hospitals and specialty cardiovascular centers. Continued investment in R&D, coupled with clinical evidence supporting new graft technologies, is driving adoption and strengthening market growth.

Asia-Pacific Vascular Graft Market Insight

The Asia-Pacific vascular graft market is poised to grow at the fastest CAGR during the forecast period of 2025 to 2032, fueled by increasing urbanization, rising prevalence of cardiovascular diseases, and growing healthcare expenditure in countries such as China and India. Expansion of tertiary care hospitals, government health initiatives, and the adoption of advanced endovascular technologies contribute to the region’s rapid market growth. Furthermore, rising awareness of cardiovascular interventions and increasing accessibility to advanced healthcare services are driving higher adoption rates of vascular graft procedures.

Japan Vascular Graft Market Insight

The Japan vascular graft market is gaining momentum due to the country’s advanced healthcare system, increasing prevalence of cardiovascular conditions, and demand for minimally invasive treatment options. Japanese hospitals and specialty centers are increasingly adopting high-performance grafts, endovascular devices, and innovative procedural techniques. Additionally, an aging population and rising cardiovascular health awareness are expected to spur demand for safer, effective, and technologically advanced vascular interventions across both residential and clinical settings.

China Vascular Graft Market Insight

The China vascular graft market accounted for the largest market revenue share in Asia-Pacific in 2024, attributed to expanding healthcare infrastructure, growing cardiovascular disease prevalence, and strong adoption of advanced vascular interventions. China is witnessing rapid growth in tertiary care hospitals and specialty cardiovascular centers, with increasing availability of bioengineered grafts and minimally invasive endovascular solutions. Government initiatives to enhance healthcare access, rising patient awareness of cardiovascular treatment options, and the presence of domestic and international industry players are key factors propelling the market in China.

Vascular Graft Market Share

The Vascular Graft industry is primarily led by well-established companies, including:

• Medtronic (Ireland)
• Terumo Corporation (Japan)
• Getinge (Sweden)
• Cook Medical (U.S.)
• Boston Scientific Corporation (U.S.)
• CryoLife, Inc. (U.S.)
• B. Braun SE (Germany)
• Jotec GmbH (Germany)
• LeMaitre Vascular, Inc. (U.S.)
• Terumo Corporation (U.K.)
• Synovis Life Technologies, Inc. (U.S.)
• AorTech International PLC (U.K.)

Latest Developments in Global Vascular Graft Market

• In June 2025, Aortyx, a Barcelona-based medical device company, secured €13.8 million in a Series A funding round to advance clinical trials of its bioabsorbable vascular patch. This innovative device aims to provide a minimally invasive solution for treating aortic dissections, a condition affecting over 50,000 individuals annually in Europe. The funding was led by Ship2B Ventures, Clave Capital, and the European Investment Fund, among others
• In July 2023, Kerecis, an Icelandic medical technology company specializing in fish skin-based grafts, was acquired by Danish firm Coloplast for USD 1.2 billion. Kerecis utilizes decellularized cod skin to create grafts that enhance wound healing, offering a natural alternative to synthetic materials. This acquisition aims to strengthen Coloplast's portfolio in advanced wound care and tissue regeneration
• In April 2021, Fractyl Health, a company focused on metabolic disease treatments, received FDA Breakthrough Device Designation for its Revita system. The system is designed to treat type 2 diabetes by targeting the duodenum to improve insulin sensitivity. This designation accelerates the development and review process, highlighting the device's potential to address unmet medical needs
• In 2021, Aroa Biosurgery, a New Zealand-based company specializing in regenerative medicine, received FDA clearance for its Myriad Morcells. These devices are designed for use in plastic and reconstructive surgery, offering solutions that promote tissue repair and healing. The clearance supports Aroa's expansion into the U.S. market

SKU-27028